Actavis has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration.The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech.
BioAlliance Pharma SA and Topotarget A/S today announced their intention to merge to create an...
Epirus Biopharmaceuticals, Inc. and Zalicus Inc., announced today that they have entered into a...
Moberg Pharma AB has entered into a definitive agreement with Oracain II Aps (Denmark) to...
Will Sun’s latest acquisition change the global pharma landscape, or result in yet another problem-filled “me too” pharma company?
Swiss drug maker Roche plans to buy IQuum, Inc., a U.S. company that specializes in molecular diagnostics and sample testing, in a deal worth up to $450 million.
India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion deal, the companies said Monday.
Mallinckrodt is buying California-based Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion that will help to diversify further the Irish company's business.
Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses. Meda AB says talks between the two companies have stopped "without further actions."
Actavis today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.
RestorGenex Corporation announced today the closing of its acquisition of two biopharmaceuticals companies, Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.
Nordion Inc., a provider of products and services to the global health science market, announced that it has entered into a definitive agreement to be acquired by Sterigenics, a provider of sterilization services and a portfolio company of GTCR LLC.
Otsuka Pharmaceutical Co., Ltd.has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen ® and to an enzyme inhibitor, E7727.
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5M.
Johnson & Johnson today announced that it has accepted the binding offer from The Carlyle Group, which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments.
AMRI has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million.
Horizon Pharma Inc. will acquire Vidara Therapeutics for a "tax-efficient corporate structure."
Horizon Pharma Inc. plans to buy the privately held Vidara Therapeutics International Ltd. in a cash-and-stock deal that will add the immune system disorder drug Actimmune to the specialty drugmaker's product portfolio.
Mallinckrodt plc (NYSE:MNK) today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion.
Intrexon Corporation, a synthetic biology company, has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and complex chemistry industries.
Charles River Laboratories International, has entered into a definitive agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus.
With the merger, the company extends its global footprint to include 20 operational offices in 15 countries, including new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
The British consumer goods company Reckitt Benckiser is buying K-Y personal lubricants from U.S. health care giant Johnson & Johnson. Terms of the deal were not disclosed Monday by Reckitt Benckiser, which expects to close the acquisition by the middle of the year.
With these acquisitions, Stratus, which will be renamed RestorGenex, plans to create a pharmaceutical company with an initial focus on dermatology, ocular diseases and women's health.
Flush with cash and high stock prices, companies are buying up the competition at levels not seen since the dotcom bubble. And with Washington providing more clarity on government spending plans, CEOs are more confident their expansion hopes will pan out — especially if the economy keeps growing.
Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with hyponatremia. The product was developed and registered by Astellas and was commercially launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia.
Valeant Pharmaceuticals is seeing more clearly the merits of its acquisition last summer of eye care company Bausch and Lomb and remains on the hunt for another big acquisition this year.
Endo Health Solutions Inc. has announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. were approved by Endo's shareholders.
Eli Lilly is buying a privately held, poultry vaccine maker to strengthen its Elanco animal health subsidiary. No terms were released, but Lilly said Monday that its 2014 earnings forecast will be trimmed due to acquisition costs.
- Page 1